Identification of key modules in metabolic syndrome induced by second-generation antipsychotics based on co-expression network analysis
Background: Second-generation antipsychotics (SGAs) frequently cause metabolic syndrome (MetS), which raises the risk of heart disease, type 2 diabetes, morbid obesity, atherosclerosis, and hypertension. MetS also impairs cognitive function in patients with schizophrenia. However, the fundamental re...
Main Authors: | Ying Sun, Cuizhen Zhu, Lixuan Huang, Chao Luo, Peijun Ju, Jianhua Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-12-01
|
Series: | Computational and Structural Biotechnology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037024000035 |
Similar Items
-
A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers
by: Demet Sağlam Aykut, et al.
Published: (2018-07-01) -
The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population
by: Osama Abo Alrob, et al.
Published: (2019-06-01) -
Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications
by: M S Karthik, et al.
Published: (2014-01-01) -
Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
by: Olga Płaza, et al.
Published: (2022-12-01) -
Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
by: Diana Grajales, et al.
Published: (2019-10-01)